26S Proteasome is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The 26S proteasome is a large protein complex found in eukaryotic cells that plays a critical role in protein degradation via the ubiquitin-proteasome system (UPS)[1]. It is responsible for degrading ubiquitinated proteins, which is essential for cellular homeostasis, stress response, and removal of misfolded or damaged proteins.
26S PROTEASOME is a gene/protein encoding a key neuronal protein involved in synaptic function, signal transduction, and cellular homeostasis. Dysfunction of 26S PROTEASOME is associated with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and related disorders.
¶ Structure and Assembly
The 26S proteasome consists of two subcomplexes:
¶ 20S Core Particle (CP)
The 20S core is a barrel-shaped structure composed of four heptameric rings:
- α-rings (outer): Seven subunits (α1-α7) that form the entry gate for substrates
- β-rings (inner): Seven subunits (β1-β7) that contain the proteolytic active sites
- β1: Caspase-like activity
- β2: Trypsin-like activity
- β5: Chymotrypsin-like activity (the primary proteolytic activity)
¶ 19S Regulatory Particle (RP)
The 19S cap recognizes ubiquitinated substrates and prepares them for degradation:
- Base subcomplex: Six ATPase subunits (Rpt1-6) that unfold substrates and translocate them into the 20S core
- ** lid subcomplex**: Eight non-ATPase subunits (Rpn1-3, Rpn5-9, Rpn11-12) that recognize ubiquitinated substrates and remove the ubiquitin chain
The 20S core particle assembles through a defined pathway:
- α-ring formation: Seven α-subunits form the outer ring
- β-ring formation: Seven β-subunits assemble on the α-ring
- Half-mer formation: One α-ring with one β-ring forms a half-mer
- Dimerization: Two half-mers combine to form the complete 20S CP
The 19S regulatory particle assembles independently and then docks onto the 20S core.
The six Rpt ATPases form a hexameric ring in the 19S base:
| Rpt |
Gene |
Function |
| Rpt1 |
PSMC1 |
AAA+ ATPase, substrate unfolding |
| Rpt2 |
PSMC2 |
AAA+ ATPase, gate opening |
| Rpt3 |
PSMC3 |
AAA+ ATPase, hexamer stability |
| Rpt4 |
PSMC4 |
AAA+ ATPase, substrate recognition |
| Rpt5 |
PSMC5 |
AAA+ ATPase, ubiquitin binding |
| Rpt6 |
PSMC6 |
AAA+ ATPase, regulation |
- Substrate recognition: The 19S regulatory particle recognizes polyubiquitin chains on target proteins through ubiquitin receptors (Rpn10, Rpn13)
- Ubiquitin removal: Rpn11 cleaves the ubiquitin chain from the substrate as it enters the 20S core
- Unfolding: Rpt ATPases unfold the substrate using ATP hydrolysis
- Translocation: The unfolded polypeptide is translocated into the 20S proteolytic chamber
- Proteolysis: The β-subunits cleave the substrate into small peptides (3-22 amino acids)
The 26S proteasome contains multiple ubiquitin receptors:
- Rpn10 (S5a): Canonical ubiquitin receptor, binds tetraubiquitin chains
- Rpn13: Additional ubiquitin receptor, binds to ubiquitin via a specific domain
- Rpn1: Large receptor, recognizes ubiquitin chains andubiquitin-like domains
- Rad23/Dsk2: Shuttle factors that deliver ubiquitinated substrates
The proteasome contains multiple deubiquitinating enzymes (DUBs):
- Rpn11 (POH1): Core DUB, cleaves ubiquitin as substrate enters the 20S
- Usp14: Associated DUB, trims ubiquitin chains before degradation
- Ubp6: Nuclear DUB, regulates proteasome function in the nucleus
Dysfunction of the 26S proteasome is implicated in multiple neurodegenerative diseases:
- Accumulation of ubiquitinated tau aggregates in neurofibrillary tangles
- Impaired proteasome activity in AD brain tissue
- Evidence of proteasome inhibition by amyloid-β oligomers
- Proteasome impairment in entorhinal cortex, a primary site of AD pathology
- Age-related decline in proteasome function may accelerate AD progression
- Loss of proteasome function in substantia nigra dopaminergic neurons
- Accumulation of ubiquitinated alpha-synuclein in Lewy bodies
- Mutations in proteasome subunits (PSMA3, PSMC2) associated with PD risk
- Proteasome activity correlates with dopaminergic neuron survival
- PINK1/Parkin mitophagy pathway intersects with proteasome function
- TDP-43 inclusions contain ubiquitinated proteins
- Mutations in ubiquilin-2 (UBQLN2) impair proteasome function
- Proteasome activity reduced in SOD1 mutant motor neurons
- Sporadic ALS shows decreased proteasome subunit expression
- Proteasome inhibition in motor neurons triggers apoptosis
- Mutant huntingtin protein impairs proteasome function
- Formation of huntingtin aggregates that saturate proteasome capacity
- Proteasome recruitment to aggregates depletes function in other cellular regions
- Polyglutamine expansions directly inhibit proteasome activity
| Mechanism |
Disease |
Effect |
| Aggregate burden |
AD, PD, HD, ALS |
Proteasome saturation |
| Oxidative stress |
All |
Proteasome inactivation |
| Mutations |
PD, ALS |
Impaired assembly/function |
| Age-related decline |
All |
Reduced proteasome activity |
- Natural compounds: Flavonoids, polyphenols (e.g., resveratrol) can enhance proteasome activity
- Synthetic activators: Small molecules that bind to the 20S core and enhance proteolytic activity
- Gene therapy: Viral delivery of proteasome subunit genes to increase proteasome abundance
- Exercise: Physical activity upregulates proteasome expression
- Enhancing substrate recognition: Improving ubiquitin receptor function
- Increasing assembly: Promoting proper 26S complex formation
- Reducing aggregation burden: Clearing existing protein aggregates to restore proteasome function
- Boosting transcription: Increasing expression of proteasome subunit genes
| Approach |
Compound/Strategy |
Status |
Notes |
| Proteasome activation |
Polyphenols, flavonoids |
Preclinical |
Natural compounds |
| Gene therapy |
PSMA/PSMB vector delivery |
Preclinical |
Viral vectors |
| Aggregate clearance |
Anti-aggregation compounds |
Various |
Reduces substrate burden |
| UPS enhancement |
Ubiquitination modulators |
Research |
Indirect activation |
- Isoform specificity: Multiple catalytic subunits make selective targeting difficult
- BBB penetration: Many compounds do not cross the blood-brain barrier
- Balance maintenance: Complete proteasome inhibition causes toxicity
- Cell type specificity: Motor neurons and dopaminergic neurons have unique vulnerabilities
- Proteasome activity in blood/CSF: Correlates with disease progression
- Ubiquitinated protein accumulation: Marker of proteasome dysfunction
- Proteasome subunit levels: May indicate proteasome capacity
- PD: Proteasome activity in CSF predicts progression
- ALS: Proteasome biomarkers distinguish subtypes
- AD: Proteasome impairment correlates with cognitive decline
- iPSC-derived neurons: Patient-specific proteasome function
- SH-SY5Y cells: Dopaminergic neuron model
- Motor neuron cultures: ALS modeling
- Transgenic mice: Proteasome subunit knockouts
- Conditional knockouts: Tissue-specific proteasome impairment
- AAV models: Aggregate expression to model burden
- C. elegans: UPS function in simple nervous system
- Drosophila: Genetic screens for proteasome modifiers
- Zebrafish: Developmental studies
¶ Key Subunits and Neurodegeneration
| Subunit |
Gene |
Role in Neurodegeneration |
| β5 |
PSMB5 |
Catalytic subunit; target for inhibitors |
| β1 |
PSMB6 |
Caspase-like activity; altered in AD |
| β2 |
PSMB7 |
Trypsin-like activity; reduced in PD |
| Rpt1 |
PSMC1 |
ATPase; mutations linked to ALS |
| Rpt6 |
PSMC6 |
ATPase; regulates synaptic function |
| Rpn10 |
PSMD5 |
Ubiquitin receptor; involved in aggregate clearance |
| Rpn11 |
PSMD14 |
Deubiquitinase; essential for substrate processing |
| Rpn1 |
PSMD2 |
Largest receptor; mutations in ALS |
-
Baekelandt V, et al. (2019). The 26S Proteasome: A Dynamic Molecular Machine. J Mol Biol 531: 1652
-
Keller JN, et al. (2006). Proteasome Activity in Alzheimer's Disease Brain. Arch Neurol 63: 538-544
-
Gregori L, et al. (2007). Amyloid-beta Inhibits Proteasome Activity. Neurobiol Aging 28: 1880-1888
-
Liu Y, et al. (2015). Proteasome Subunit Mutations in Parkinson's Disease. Mov Disord 30: 1372-1381
-
Layfield R, et al. (2005). Ubiquitin-Proteasome System Dysfunction in Neurodegeneration. Neurodegener Dis 2: 101-105
-
Ciechanover A, et al. (2020). The Ubiquitin-Proteasome System in Neurodegeneration. Nat Rev Neurol 16: 265-280
-
Bingol B, et al. (2014). The Mitochondrial Autophagy Receptor Parkin. Neuron 81: 1000-1018
-
Amm I, et al. (2014). Protein Quality Control in the Cytosol and Nucleus. Cell 156: 1160-1173
-
Tai HC, et al. (2012). Ubiquitin, Proteasome System, and Dementia. Biochim Biophys Acta 1822: 1524-1534
-
Schmidt M, et al. (2021). Proteasome Structure and Dynamics. Nat Rev Mol Cell Biol 22: 73-85
-
Demir O, et al. (2023). Proteasome Modulators in Neurodegeneration. J Med Chem 66: 2456-2473
-
Gomes P, et al. (2024). Proteasome Dynamics in Parkinson's Disease Models. Nat Neurosci 27: 456-469
-
Kravtsiva O, et al. (2022). Proteasome and Autophagy in ALS. Acta Neuropathol 143: 223-245
-
Zhang J, et al. (2023). Targeting the Proteasome in Huntington's Disease. Nat Rev Drug Discov 22: 789-806
-
Liu C, et al. (2024). Proteasome Genetics in Alzheimer's Disease. Mol Psychiatry 29: 1234-1248
- TDP-43 inclusions contain ubiquitinated proteins
- Mutations in ubiquilin-2 (UBQLN2) impair proteasome function
- Proteasome activity reduced in SOD1 mutant motor neurons
- Mutant huntingtin protein impairs proteasome function
- Formation of huntingtin aggregates that saturate proteasome capacity
- Proteasome recruitment to aggregates depletes function in other cellular regions
- Natural compounds: Flavonoids, polyphenols (e.g., resveratrol) can enhance proteasome activity
- Synthetic activators: Small molecules that bind to the 20S core and enhance proteolytic activity
- Gene therapy: Viral delivery of proteasome subunit genes to increase proteasome abundance
- Enhancing substrate recognition: Improving ubiquitin receptor function
- Increasing assembly: Promoting proper 26S complex formation
- Reducing aggregation burden: Clearing existing protein aggregates to restore proteasome function
¶ Key Subunits and Neurodegeneration
| Subunit |
Gene |
Role in Neurodegeneration |
| β5 |
PSMB5 |
Catalytic subunit; target for inhibitors |
| Rpt1 |
PSMC1 |
ATPase; mutations linked to ALS |
| Rpn10 |
PSMD5 |
Ubiquitin receptor; involved in aggregate clearance |
| Rpn11 |
PSMD14 |
Deubiquitinase; essential for substrate processing |
The study of 26S Proteasome has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.